{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zeng L"],"funding":["National Natural Science Foundation of China (National Science Foundation of China)"],"pagination":["567"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12808239"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["Immune checkpoint inhibitors (ICIs) have improved survival in advanced non-small cell lung cancer (NSCLC), yet resistance remains a major challenge. Here, we report the results from cohort A of a multi-cohort, phase II, open-label trial [NCT04777084], evaluating the efficacy and safety of IBI318 (a bispecific anti-PD-1/PD-L1 antibody, 300 mg intravenous every 2 weeks) plus lenvatinib (a receptor tyrosine kinase inhibitor, 8 mg orally daily). Forty patients with advanced NSCLC and acquired resistance to first-line ICIs were enrolled and received at least 1 cycle of the study regimen. The primary endpoint of 12-week objective response rate was 40.0% (95% CI: 24.9-56.7), satisfying prespecified efficacy threshold. Secondary endpoints included other efficacy endpoints and safety. Median progre"],"journal":["Nature communications"],"pubmed_title":["PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial."],"pmcid":["PMC12808239"],"funding_grant_id":["82173338","82222048"],"pubmed_authors":["Zhang G","Ruan Z","Liu L","Deng J","Deng L","Fang C","Zou C","Wang J","Song L","Xiong Y","Jiang W","Zhou C","Wei S","Chen Y","Chen X","Chen S","Wang Z","Zhou H","Yang H","Zeng L","Yang N","Xu Q","Zeng Z","Yang D","Sun Y","Li Y","Huang Z","Li T","Zhang Y","Zhang X","Qin H","Xu S","Zeng F","Yan H","Dai J"],"additional_accession":[]},"is_claimable":false,"name":"PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.","description":"Immune checkpoint inhibitors (ICIs) have improved survival in advanced non-small cell lung cancer (NSCLC), yet resistance remains a major challenge. Here, we report the results from cohort A of a multi-cohort, phase II, open-label trial [NCT04777084], evaluating the efficacy and safety of IBI318 (a bispecific anti-PD-1/PD-L1 antibody, 300 mg intravenous every 2 weeks) plus lenvatinib (a receptor tyrosine kinase inhibitor, 8 mg orally daily). Forty patients with advanced NSCLC and acquired resistance to first-line ICIs were enrolled and received at least 1 cycle of the study regimen. The primary endpoint of 12-week objective response rate was 40.0% (95% CI: 24.9-56.7), satisfying prespecified efficacy threshold. Secondary endpoints included other efficacy endpoints and safety. Median progre","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-15T11:17:35.328Z","creation":"2026-07-04T03:12:16.575Z"},"accession":"S-EPMC12808239","cross_references":{"pubmed":["41398162"],"doi":["10.1038/s41467-025-67262-x"]}}